Study S001718

Comparison of Efficacy and Safety of POSE 2.0 Procedure Compared to GLP-1 Agonist in a Cohort of Patients for Management of Obesity: a Single-center Randomized Crossover-controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05705388
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: UNKNOWN
Enrollment: 50
Start: 2023-01-16
Primary completion: 2025-01-03
Lead sponsor: Emirates Health Services (EHS)
Conditions: Obesity
Interventions: DEVICE:POSE2.0 Endoscopic Gastric Remodeling; DRUG:Liraglutide injection
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Mean percent total body weight loss at 6 months in each arm of the study [6 months]
Percentage of subjects with ≥5 percent total body weight loss at 6 months in each arm at 6 months [6 months]
The incidence, frequency, and severity of adverse events related to treatment with the device and procedure as well as medication will be reported. [at 6 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.